Abstracts tagged "COVID-19"

Abstract Number: 1198 • ACR Convergence 2022
Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Bradley Pearce¹, S. Sam Lim¹, Cristina Drenkard¹ and Laura Plantinga¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: The disruption of the COVID-19 pandemic presented an opportunity for researchers to develop and administer remote versions of measures for ongoing studies. In an…
Abstract Number: 1525 • ACR Convergence 2022
Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey
Sakir Ahmed¹, Naveen R², John Pauling³, Darpan Thakare², Chris Wincup⁴, Nicoletta Del Papa⁵, Gianluca Sambataro⁶, Fabiola Atzeni⁷, SIMONE PARISI⁸, Marcello Govoni⁹, Elena Bartoloni Bocci¹⁰, Gian Domenico Sebastiani¹¹, Enrico Fusaro¹², Marco Sebastiani¹³, Luca Quartuccio¹⁴, Franco Franceschini¹⁵, Pier Paolo Sainaghi¹⁶, Giovanni Orsolini¹⁷, Rossella De Angelis¹⁸, Maria Giovanna Danielli¹⁹, Vincenzo Venerito²⁰, Parikshit Sen²¹, Minchul Kim²², Abraham Edgar Gracia-Ramos²³, Akira Yoshida²⁴, James B. Lilleker²⁵, Vishwesh Agarwal²⁶, Sinan Kardes²⁷, Jessica Day²⁸, Mrudula Joshi²⁹, Marcin Milchert³⁰, Tamer A Gheita³¹, Babur Salim³², Ioannis Parodis³³, Albert Selva O’Callaghan³⁴, Elena Nikiphorou³⁵, Tulika Chatterjee²², Ai Lyn Tan³⁶, Arvind Nune³⁷, Lorenzo Cavagna³⁸, Samuel Shinjo³⁹, Nelly Ziade⁴⁰, Johannes Knitza⁴¹, Hector Chinoy⁴², Oliver Distler⁴³, Masataka Kuwana⁴⁴, Rohit Aggarwal⁴⁵, Latika Gupta⁴⁶, Vikas Agarwal² and Ashima Makol⁴⁷, ¹Kalinga Institute of Medical Sciences, Bhubaneswar, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University College London, London, United Kingdom, ⁵Unità operativa complessa (UOC) Day Hospital Reumatologia via Gaetano Pini 9, Centro Specialistico Ortopedico Traumatologico, Gaetano Pini-CTO, Milano, Italy, ⁶Medico Immunologia e reumatologia presso, Artoreuma S.R.L., Cors S, Mascalucia, ⁷Rheumatology Unit, University of Messina, Messina, Italy, ⁸Italian Society for Rheumatology, Turin, Italy, ⁹S. Anna Hospital and University of Ferrara, Ferrara, Italy, ¹⁰Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ¹¹U.O.C. Reumatologia, Ospedale San Camillo-Forlanini,, Roma, ¹²Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹³Azienda Policlinico di Modena, Modena, Italy, ¹⁴Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy, ¹⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹⁶Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy, ¹⁷Department of Medicine, Rheumatology Unit, University of Verona, Verona, Verona, ¹⁸Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy, ¹⁹Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle, Marche, Italy, ²⁰Department of Emergency and Organ Transplantations-Rheumatology Unit, University of Bari "Aldo Moro", Bari, Italy, ²¹Maulana Azad Medical College, New Delhi, India, ²²University of Illinois College of Medicine Peoria, Peoria, IL, ²³Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁴Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ²⁵The University of Manchester, Manchester, United Kingdom, ²⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ²⁷Istanbul University, Istanbul, Turkey, ²⁸Walter and Eliza Hall Institute, Melbourne, Australia, ²⁹Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ³⁰Pomeranian Medical University in Szczecin, Szczecin, Poland, ³¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ³²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ³³Karolinska Institutet, Stockholm, Sweden, ³⁴Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³⁵Leiden University Medical Center & King's College London, London, United Kingdom, ³⁶University of Leeds, Leeds, United Kingdom, ³⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ³⁸Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ³⁹Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁴⁰Saint-Joseph University, Beirut, Lebanon, ⁴¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴²The University of Manchester, Sale, United Kingdom, ⁴³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴⁴Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴⁶Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ⁴⁷Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (AIRDs) are considered more susceptible to break through infection (BI) following vaccination due to their immunosuppressed status and…
Abstract Number: 1870 • ACR Convergence 2022
Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody Positive Dermatomyositis
Richard Seto¹, Sangmee Bae¹ and Christina Charles-Schoeman², ¹University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Patients with dermatomyositis (DM) and antibodies (ab) to melanoma differentiation associated gene 5 (MDA5) share similar clinical characteristics to patients infected with the severe…
Abstract Number: 2178 • ACR Convergence 2022
BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients
Yolanda Braun-Moscovici¹, Marielle Kaplan¹, Maya Braun², Doron Markovits³, Sami Giryes³, Kohava Toledano³, Yonit Tavor³, Katya Dolnikov³, Rula Daood³ and Alexandra Balbir-Gurman⁴, ¹Rambam Health Care Campus and Rappaport Faculty of Medicine, Haifa, Israel, ²Hebrew University of Jerusalem, Bioinformatics, Jerusalem, Israel, ³Rambam Health Care Campus, Haifa, Israel, ⁴Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel
Background/Purpose: In the begining of pandemic and till spring 2021 there were no clinical and laboratory data regarding sefety and efficacy of mRNA vaccines against…
Abstract Number: 0141 • ACR Convergence 2022
Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
Yasmin Gerais¹, Chenyu Sun¹, Bethany King², Scott Lowe³, Biniyam Mohammed¹, Rachel Bentley³, Yaru Li⁴, Binyu Wei⁵ and Chuanhui Xu⁶, ¹Ascension Saint Joseph hospital, Chicago, IL, ²MercyOne Des Moines Medical center, Des Moines, IA, ³College of Osteopathic Medicine, Kansas City University, Kansas, MO, ⁴Swedish Hospital, Chicago, IL, ⁵Harvard Medical School, Boston, MA, ⁶Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: Rituximab targets the CD20 antigen to deplete B cells and is indicated for a number of autoimmune diseases and other conditions. Accumulating data suggest…
Abstract Number: 0508 • ACR Convergence 2022
Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…
Abstract Number: 0751 • ACR Convergence 2022
Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Smruthi Ramachandran¹, Jenny Leese², Stephanie Therrien³, Catherine L. Backman¹, Jasmin Ma⁴, Kelly English⁵, Eileen Davidson⁶, Shanon McQuitty⁷, Alison Hoens⁵, Cheryl Koehn⁸, James Gavin⁹, jo Adams⁹ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, ⁷Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, ⁸Arthritis Consumer Experts, Vancouver, BC, Canada, ⁹University of Southampton, Southampton, United Kingdom
Background/Purpose: The COVID-19 pandemic has provided opportunity to increase integration of virtual healthcare with in-person medical practices. Individuals with rheumatoid arthritis (RA) continue to self-manage…
Abstract Number: 0786 • ACR Convergence 2022
Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
Carolina A Isnardi¹, Osvaldo Luis Cerda¹, MARGARITA LANDI², Leonel Cruces³, Emilce Edith Schneeberger¹, Claudia Calle montoro², Maria Agustina Alfaro⁴, Brian Manases roldan⁴, Andrea Belen Gomez Vara¹, Pamela Giorgis⁴, Roberto Alejandro Ezquer⁴, María G Crespo Rocha⁴, Camila R Reyes Gómez⁴, maria de los angeles correa⁴, Marcos Rosemffet⁵, Virginia Carrizo Abarza⁴, Santiago Catalan Pellet⁶, Miguel Perandones⁴, Cecilia Reimundes⁷, Yesica Longueira³, Gabriela Turk³, María Florencia Quiroga³, Natalia Laufer³, Rosana Quintana⁸, Maria De la Vega⁹, Nicolás Kreplak¹⁰, Marina Pifano¹⁰, Pablo Maid², Guillermo Pons-Estel¹¹ and Gustavo Citera¹, ¹Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ²Austral University Hospital, Rheumatology Department, Buenos Aires, Argentina, ³Universidad de Buenos Aires. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS). Facultad de Medicina, Buenos Aires, Argentina, ⁴Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁶Austral University Hospital, Rheumatology Department, Lincoln, Argentina, ⁷Austral University Hospital, Rheumatology Department, Pilar, Argentina, ⁸Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁹Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹⁰Ministry of Health of the Province of Buenos Aires, Buenos Aires, Argentina, ¹¹CREAR, Rosario, Argentina
Background/Purpose: Patients with immune mediated diseases achieve lower seroconversion rates to COVID19 vaccines compared to healthy controls, which is why these patients are a prioritized…
Abstract Number: 0838 • ACR Convergence 2022
Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
Lisa Mandl¹, Benjamin Swett¹, Robyn Lipschultz¹, Myriam Lin¹, Alison Zhao², Carola Hanreich¹, Dongmei Sun¹, Kethy Jules-elysee¹ and Friedrich Boettner¹, ¹Hospital for Special Surgery, New York, NY, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Background/Purpose: Over 520 million people have been infected by SARS-CoV-2. In 10-40%, disabling symptoms such as fatigue and dyspnea can persist. Risk factors for poor…
Abstract Number: 1201 • ACR Convergence 2022
Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
Emily G Oakes¹, Jack Ellrodt¹, Roberta Alexander², John Conklin², May Choi³, Hongshu Guan¹, Sara Tedeschi¹, Jeffrey Sparks⁴, Siobhan Case⁵, Tiffany Hsu¹, Daniel Solomon¹, Anna Jonsson¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Exagen, Inc., Vista, CA, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA
Background/Purpose: Onset of autoimmune connective tissue disease (CTD) after COVID-19 infection has been reported and complement activation has been implicated. We examined common autoimmune rheumatic…
Abstract Number: 1591 • ACR Convergence 2022
Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Sandra Sze-jung Wu¹, Gelareh Atefi², Meghan Moynihan³, Kristin Evans³, Liisa Palmer³, Michael Pollack², Christine Dube⁴ and Cassandra Calabrese⁵, ¹AstraZeneca, Hockessin, DE, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Torrington, CT, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…
Abstract Number: 1875 • ACR Convergence 2022
Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin
Sangmee Bae¹, emmanuelle Faure-Kumar¹, Jennifer Wang², Ani Shahbazian², linh Truong², Howard Yang², Maureen McMahon¹, John FitzGerald¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Medical Center, Los Angeles, CA, ³Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Antibodies to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) have been reported in pooled donor plasma and intravenous immunoglobulin products (IVIG) since May 2020 (C…
Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 0145 • ACR Convergence 2022
Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases
Paula María Corbalan¹, MARIANA PERA¹, Ana Lucia Barbaglia², Maria Constanza Bertolaccini³, Luciana González Lucero⁴, Raul Sueldo⁵, Rosana Nieves Chehín⁶, Rodrigo Hernán Tomas-Grau⁶, Diego Ploper⁶, Esteban Vera Pinguitore⁷, César Luis Ávila⁷, Benjamín Socías⁷, Silvia Inés Cazorla⁸, Carolina Maldonado Galdeano⁸ and VERONICA BELLOMIO⁴, ¹Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, ²Hospital Padilla, Tucumán, Argentina, ³Hospital Padilla, San Miguel de Tucuman, Argentina, ⁴Hospital Padilla, San Miguel de Tucumán, Argentina, ⁵Hospital Ángel Cruz Padilla, Tucumán, Argentina, ⁶Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA), San Miguel de Tucumán, Argentina, ⁷Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA), San Miguel de Tucumán, Tucuman, Argentina, ⁸Centro de Referencia para Lactobacilos (CERELA), San Miguel de Tucumán, Tucuman, Argentina
Background/Purpose: Several trials have reported lower seroconversion rates in patients with autoimmune rheumatic diseases than in healthy patients. In Argentina, the vaccines against SARS-CoV-2 that…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].